Brokerages Set GoodRx Holdings, Inc. (NASDAQ:GDRX) PT at $8.37

GoodRx Holdings, Inc. (NASDAQ:GDRX) has been assigned a consensus recommendation of “Moderate Buy” from the sixteen brokerages that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, nine have given a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $8.37.

A number of equities research analysts have commented on the company. Citigroup decreased their price target on GoodRx from $10.00 to $7.00 and set a “buy” rating for the company in a research note on Wednesday, November 13th. Mizuho assumed coverage on shares of GoodRx in a research note on Wednesday, December 4th. They issued a “neutral” rating and a $5.00 target price for the company. Barclays dropped their target price on shares of GoodRx from $10.00 to $6.00 and set an “overweight” rating on the stock in a research report on Monday, November 11th. Finally, Morgan Stanley decreased their price target on shares of GoodRx from $7.00 to $6.00 and set an “equal weight” rating for the company in a report on Tuesday, December 17th.

GoodRx Stock Performance

Shares of GDRX opened at $4.62 on Friday. The company has a current ratio of 5.48, a quick ratio of 5.48 and a debt-to-equity ratio of 0.70. The firm has a market cap of $1.76 billion, a PE ratio of -154.00, a P/E/G ratio of 3.54 and a beta of 1.29. GoodRx has a 12 month low of $4.09 and a 12 month high of $9.26. The stock has a fifty day moving average price of $5.09 and a 200-day moving average price of $6.82.

Institutional Investors Weigh In On GoodRx

Several hedge funds have recently bought and sold shares of the stock. Liontrust Investment Partners LLP acquired a new position in shares of GoodRx in the 2nd quarter valued at $520,000. Legato Capital Management LLC purchased a new stake in shares of GoodRx during the 2nd quarter worth about $805,000. Picton Mahoney Asset Management boosted its stake in shares of GoodRx by 24.3% during the 2nd quarter. Picton Mahoney Asset Management now owns 607,090 shares of the company’s stock worth $4,736,000 after acquiring an additional 118,703 shares in the last quarter. ClariVest Asset Management LLC grew its position in shares of GoodRx by 27.4% during the 2nd quarter. ClariVest Asset Management LLC now owns 195,722 shares of the company’s stock valued at $1,527,000 after acquiring an additional 42,097 shares during the period. Finally, American Century Companies Inc. purchased a new position in shares of GoodRx in the 2nd quarter valued at about $18,183,000. Hedge funds and other institutional investors own 63.77% of the company’s stock.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.